Current therapies in Hodgkin's disease

K. E. Kogel; J. W. Sweetenham

doi:10.1007/s00259-003-1156-7

Current therapies in Hodgkin's disease

K. E. Kogel, J. W. Sweetenham

Research output: Contribution to journal › Review article › peer-review

21 Scopus citations

Abstract

Advances in the treatment of Hodgkin's disease (HD) have resulted in cure rates of greater than 80%. This remarkable achievement has occurred in the past 50 years secondary to improvements in combination chemotherapy and radiotherapy. Over the last several decades, with the increase in long-term survivors of HD, it has become evident that cure is not the only issue, and late side-effects of treatment, including secondary malignancies and impaired fertility, are of major concern as well. As a result, attempts to improve response and survival rates by intensifying therapy must be countered against the potential for long-term toxicity.

Original language	English (US)
Pages (from-to)	S19-S27
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	30
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1007/s00259-003-1156-7
State	Published - Jun 1 2003
Externally published	Yes

Keywords

Early-stage disease
Hodgkin's disease
Long-term toxicity
Treatment

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00259-003-1156-7

Cite this

@article{ee87e668a99f402b9210dff613e3dafe,

title = "Current therapies in Hodgkin's disease",

abstract = "Advances in the treatment of Hodgkin's disease (HD) have resulted in cure rates of greater than 80%. This remarkable achievement has occurred in the past 50 years secondary to improvements in combination chemotherapy and radiotherapy. Over the last several decades, with the increase in long-term survivors of HD, it has become evident that cure is not the only issue, and late side-effects of treatment, including secondary malignancies and impaired fertility, are of major concern as well. As a result, attempts to improve response and survival rates by intensifying therapy must be countered against the potential for long-term toxicity.",

keywords = "Early-stage disease, Hodgkin's disease, Long-term toxicity, Treatment",

author = "Kogel, {K. E.} and Sweetenham, {J. W.}",

year = "2003",

month = jun,

day = "1",

doi = "10.1007/s00259-003-1156-7",

language = "English (US)",

volume = "30",

pages = "S19--S27",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Current therapies in Hodgkin's disease

AU - Kogel, K. E.

AU - Sweetenham, J. W.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Advances in the treatment of Hodgkin's disease (HD) have resulted in cure rates of greater than 80%. This remarkable achievement has occurred in the past 50 years secondary to improvements in combination chemotherapy and radiotherapy. Over the last several decades, with the increase in long-term survivors of HD, it has become evident that cure is not the only issue, and late side-effects of treatment, including secondary malignancies and impaired fertility, are of major concern as well. As a result, attempts to improve response and survival rates by intensifying therapy must be countered against the potential for long-term toxicity.

AB - Advances in the treatment of Hodgkin's disease (HD) have resulted in cure rates of greater than 80%. This remarkable achievement has occurred in the past 50 years secondary to improvements in combination chemotherapy and radiotherapy. Over the last several decades, with the increase in long-term survivors of HD, it has become evident that cure is not the only issue, and late side-effects of treatment, including secondary malignancies and impaired fertility, are of major concern as well. As a result, attempts to improve response and survival rates by intensifying therapy must be countered against the potential for long-term toxicity.

KW - Early-stage disease

KW - Hodgkin's disease

KW - Long-term toxicity

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0037790657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037790657&partnerID=8YFLogxK

U2 - 10.1007/s00259-003-1156-7

DO - 10.1007/s00259-003-1156-7

M3 - Review article

C2 - 12721766

AN - SCOPUS:0037790657

SN - 1619-7070

VL - 30

SP - S19-S27

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - SUPPL. 1

ER -

Current therapies in Hodgkin's disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this